New therapies in squamous cell carcinoma of the head and neck: is the future in combined therapies? Maurice Schneider Editorial 08 January 2008 Pages: 1 - 2
Phase I and pharmacokinetic study of vatalanib plus capecitabine in patients with advanced cancer Richard L. SchilskyDavid GearyMark J. Ratain Original Research 18 December 2007 Pages: 3 - 11
ErbB1–ErbB4 nuclear and cytoplasmic overexpression, ethnicity and predicted outcome in prostate cancer R. Ben-YosefD. SaridN. Yaal Hachoshen Original Research 08 December 2007 Pages: 13 - 17
From the bench to the bedside: emerging new treatments in multiple myeloma Patrick J. HaydenConstantine S. MitsiadesPaul G. Richardson Review 18 December 2007 Pages: 19 - 29
A new era in prostate cancer therapy: new targets and novel therapeutics Deborah A. BradleyMaha HussainCora N. Sternberg Review 08 December 2007 Pages: 31 - 39
From suntan to skin cancers: molecular pathways and prevention strategies Jonathan M. FisherDavid E. Fisher Review 11 December 2007 Pages: 41 - 44
Biological significance of myeloperoxidase (MPO) on green tea component, (−)-epigallocatechin-3-gallate (EGCG)-induced apoptosis: its therapeutic potential for myeloid leukemia Masahiro Kizaki Review 11 December 2007 Pages: 45 - 50
Optimizing antiangiogenic strategies: combining with radiotherapy E. Cohen-Jonathan Moyal Perspectives 08 January 2008 Pages: 51 - 56